Global Danon Disease Treatment Market, By Treatment (Medication, Cardiac ablation therapy, Physical therapy, Genetic counseling, Gene therapy, and Others), Diagnosis (Biopsy, Genetic testing, New born screening, and Others), Symptoms (Cardiomyopathy, Myopathy, Intellectual Disability, Stomach Problems, Difficulty Breathing, Visual Abnormalities, and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.
Danon Disease Treatment Market Analysis and Size
The rise in the prevalence of disease, growing government initiatives, advancement in treatment options, genetic counseling, and rising awareness are the factors that will expand the global danon disease treatment market. Increasing R&D activities and the growing focus of major pharmaceutical companies toward novel treatment therapies will provide beneficial opportunities for the global danon disease treatment market in the forecast period of 2023-2030.
There is no cure for danon disease as the treatment aims to improve symptoms, and high cost of treatment is the factor that will hamper the market growth and further challenge the market growth.
Data Bridge Market Research analyses that the danon disease treatment market, which was USD 1,647.18 million in 2023, would rocket up to USD 2,820.00 million by 2030 and is expected to undergo a CAGR of 6.50% during the forecast period. This indicates the market value. "Medication" dominates the treatment segment of the danon disease treatment market due to increasing awareness about the danon disease treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Danon Disease Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Treatment (Medication, Cardiac ablation therapy, Physical therapy, Genetic counseling, Gene therapy and Others), Diagnosis (Biopsy, Genetic testing, New born screening, and Others), Symptoms (Cardiomyopathy, Myopathy, Intellectual Disability, Stomach Problems, Difficulty Breathing, Visual Abnormalities, and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, rest of Middle East & Africa
|
|
Market Players Covered
|
Rocket Pharmaceuticals, Ltd. (U.S.), Sanofi (France), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), AstraZeneca (U.K.), and Array BioPharma (U.S.) among others.
|
|
Market Opportunities
|
|
Market Definition
Danon disease is a rare inherited metabolic disorder characterized by weakening of the heart muscle (cardiomyopathy), weakening of the muscles used for movement (skeletal muscle myopathy), and intellectual disability. It is caused due to mutations in the LAMP2 gene. This condition is a type of lysosomal storage disorder. Danon disease is also known as Glycogen Storage Disease Type 2B, Lysosomal Glycogen Storage Disease with Normal Acid Maltase. Cardiomyopathy is the most common symptom of this disorder.
The market for danon disease treatment includes the production, distribution, and sales of the medication worldwide. It involves pharmaceutical companies that manufacture danon disease treatment, healthcare facilities where it is administered, and various stakeholders such as physicians, patients, and regulatory authorities involved in its prescription, usage, and approval.
Danon Disease Treatment Market Dynamics
Drivers
- Increasing Prevalence of Danon Disease
The increasing prevalence of Danon disease is a significant driver for the global Danon disease treatment market. Danon disease is a rare genetic disorder characterized by the dysfunction of lysosomes, which are responsible for breaking down waste materials within cells. This condition primarily affects the heart, skeletal muscles, and cognitive functions.
- Improving Healthcare Infrastructure
Improving healthcare infrastructure significantly drives the global Danon disease treatment market. Danon disease, a rare genetic disorder, requires specialized medical care and access to advanced diagnostic tools, treatment facilities, and technical healthcare professionals. The availability of a robust healthcare infrastructure is vital in ensuring timely and effective diagnosis, treatment, and management of danon disease.
- Increase in Research and Development Activities
Growing R&D activities serve as a significant driver for the market. Danon disease, a rare genetic disorder, poses unique challenges in understanding its underlying mechanisms and developing effective treatment options. However, the increasing focus on rare diseases and the urgency to address unmet medical needs have led to a surge in R&D efforts dedicated to danon disease.
Opportunities
- Advancements in Medical Technology
Technological advancements in diagnostic techniques, imaging modalities, and telemedicine have improved the identification and management of danon disease. These advancements enhance the effectiveness and efficiency of danon disease treatment, further creating the opportunity for market growth.
Restraints/Challenges
- Limited awareness and understanding
Despite the increasing prevalence of Danon disease, healthcare professionals lack awareness and understanding, which can lead to delayed or misdiagnosis. This limited awareness can hinder timely access to appropriate treatments and delay the development of new therapeutic approaches.
This global danon disease treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Danon disease treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In September 2022, Rocket Pharmaceuticals, Inc. announced positive clinical updates from its Phase 1 Danon Disease Trial for RP-A501 through an oral poster session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022.
Global Danon Disease Treatment Market Scope
The market is segmented on the basis of treatment, diagnosis, symptoms, end users, and distribution channel. The growth amongst these segments will help you meagre growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.
Treatment
- Medication
- Cardiac ablation therapy
- Physical therapy
- Genetic counseling
- Gene therapy
- Others
Diagnosis
- Biopsy
- Genetic testing
- New born screening
- Others
Symptoms
- Cardiomyopathy
- Myopathy
- Intellectual Disability
- Stomach Problems
- Difficulty Breathing
- Visual Abnormalities
- Others
End User
- Clinic
- Hospital
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Danon Disease Treatment Market Regional Analysis/Insights
The market is analysed, and market size insights and trends are provided by country, treatment, diagnosis, symptoms, end users, and distribution channel as referenced above.
The countries covered in the danon disease treatment market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, rest of Middle East & Africa.
North America is dominating the market due to the increasing prevalence of the danon disease in that region. The Asia Pacific is the fastest-growing region due to the rising geriatric population in the region.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The danon disease treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for danon disease treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the danon disease treatment market. The data is available for historic period 2010-2020.
Competitive Landscape and Danon disease treatment Market Share Analysis
The Danon disease treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to danon disease treatment market.
Some of the major players operating in the danon disease treatment market are:
- Rocket Pharmaceuticals, Ltd. (U.S.)
- Sanofi (France)
- GlaxoSmithKline plc (U.K.)
- Pfizer Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- AstraZeneca (U.K.)
- Array BioPharma (U.S.)
SKU-